Cannabinoid CB2 receptor attenuates morphine-induced inflammatory responses in activated microglial cells

British Journal of Pharmacology

Volumn 166, Issue 8, 2012, Pages 2371-2385

  Merighi, Stefania ^a   Gessi, Stefania ^a   Varani, Katia ^a   Fazzi, Debora ^a   Mirandola, Prisco ^b   Borea, Pier Andrea ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Akt; CB2 receptors; ERK1 2; microglia; morphine; nitric oxide; proinflammatory cytokines; signalling pathways

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID; CANNABINOID 2 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MORPHINE; MU OPIATE RECEPTOR; NITRIC OXIDE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERANCE; ENZYME PHOSPHORYLATION; FEMALE; INFLAMMATION; MICROGLIA; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CHO CELLS; CRICETINAE; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; INDOLES; INFLAMMATION; LIPOPOLYSACCHARIDES; MAP KINASE KINASE 1; MICE; MICE, INBRED BALB C; MICROGLIA; MORPHINE; NAPHTHOLS; NITRIC OXIDE; NITRITES; RECEPTOR, CANNABINOID, CB2; RECEPTORS, OPIOID, MU; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRIAZINES;

EID: 84864466376     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01948.x     Document Type: Article

References (80)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-324.
2. Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, Pertwee RG, et al,. (2012). Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem 287: 91-104.
3. 2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160: 467-479.
4. Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, et al,. (2005). Evidence for novel cannabinoid receptors. Pharmacol Ther 106: 133-145. (Pubitemid 40613055)
5. 2 receptors in human brain inflammation. Br J Pharmacol 153: 277-285.
6. 1 receptor participation. Adv Exp Med Biol 493: 207-214. (Pubitemid 34020229)
7. 2 receptors in the brain: role in central immune function. Br J Pharmacol 153: 240-251.
8. Caivano M, Cohen P, (2000). Role of mitogen-activated protein kinase cascades in mediating lipopolysaccharide-stimulated induction of cyclooxygenase-2 and IL-1 beta in RAW264 macrophages. J Immunol 164: 3018-3025. (Pubitemid 30148961)
9. 2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2: 69-82. (Pubitemid 33086805)
10. Chao CC, Gekker G, Sheng WS, Hu S, Tsang M, Peterson PK, (1994). Priming effect of morphine on the production of tumor necrosis factor-a by microglia: implications in respiratory burst activity and human immunodeficiency virus-1 expression. J Pharmacol Exp Ther 269: 198-203. (Pubitemid 24143254)
11. Chen Y, Sommer C, (2009). The role of mitogen-activated protein kinase (MAPK) in morphine tolerance and dependence. Mol Neurobiol 40: 101-107.
12. Cichewicz DL, (2004). Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74: 1317-1324. (Pubitemid 38045526)
13. 2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol 145: 441-448. (Pubitemid 40966273)
14. Correa F, Docagne F, Clemente D, Mestre L, Becker C, Guaza C, (2008). Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E(2). Biochem J 409: 761-770. (Pubitemid 351214202)
15. 2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem Pharmacol 77: 86-100.
16. 2 receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia 58: 135-147.
17. Cui Y, Chen Y, Zhi JL, Guo RX, Feng JQ, Chen PX, (2006). Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance. Brain Res 1069: 235-243. (Pubitemid 43145918)
18. Cunha TM, Roman-Campos D, Lotufo CM, Duarte HL, Souza GR, Verri WA, et al,. (2010). Morphine peripheral analgesia depends on activation of the PI3Kgamma/AKT/nNOS/NO/KATP signalling pathway. Proc Natl Acad Sci U S A 107: 4442-4447.
19. 2) suppresses microglial activation. J Neuroinflammation 2: 29.
20. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, et al,. (2006). The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49: 67-79. (Pubitemid 43017186)
21. Fachinetti F, Del Giudice G, Furegato S, Passarotto M, Leon M, (2003). Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharide. Glia 41: 161-168. (Pubitemid 36262193)
22. Fernández-Ruiz J, (2009). The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 156: 1029-1040.
23. Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gõmez-Cañas M, Valdeolivas S, et al,. (2011). Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 163: 1365-1378.
24. da Fonseca Pacheco D, Klein A, de Castro Perez A, da Fonseca Pacheco CM, de Francischi JN, Duarte ID, (2008). The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Br J Pharmacol 154: 1143-1149. (Pubitemid 351923053)
25. Galeotti N, Stefano GB, Guarna M, Bianchi E, Ghelardini C, (2006). Signalling pathway of morphine induced acute thermal hyperalgesia in mice. Pain 123: 294-305.
26. Gertsch J, Leonti M, Raduner S, Racz I, Chen JZ, Xie XQ, et al,. (2008). Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A 105: 9099-9104.
27. Gobbi G, Mirandola P, Tazzari PL, Ricci F, Caimi L, Cacchioli A, et al,. (2003). Flow cytometry detection of serotonin content and release in resting and activated platelets. Br J Haematol 121: 892-896. (Pubitemid 36760308)
28. González-Scarano F, Baltuch G, (1999). Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 22: 219-240. (Pubitemid 29144887)
29. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR, (1982). Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 126: 131-138. (Pubitemid 13203451)
30. Henstridge CM, Balenga NA, Schröder R, Kargl JK, Platzer W, Martini L, et al,. (2010). GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 160: 604-614.
31. Hsieh GC, Pai M, Chandran P, Hooker BA, Zhu CZ, Salyers AK, et al,. (2011). Central and peripheral sites of action for CB2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol 162: 428-440.
32. Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J, et al,. (2004). A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 24: 7353-7365. (Pubitemid 39100704)
33. Jung WK, Lee DY, Park C, Choi YH, Choi I, Park SG, et al,. (2010). Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases. Br J Pharmacol 159: 1274-1285.
34. 2 receptor. Br J Pharmacol 139: 775-786. (Pubitemid 36819605)
35. Klein TW, Newton CA, (2007). Therapeutic potential of cannabinoid-based drugs. Adv Exp Med Biol 601: 395-413.
36. Klein TW, Lane B, Newton CA, Friedman H, (2000). The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 225: 1-8.
37. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K, (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105: 2699-2704. (Pubitemid 351520576)
38. Lazarczyk M, Matyja E, Lipkowski AW, (2010). A comparative study of morphine stimulation and biphalin inhibition of human glioblastoma T98G cell proliferation in vitro. Peptides 31: 1606-1612.
39. Lehnardt S, Lachance C, Patrizi S, Lefebvre S, Follett PL, Jensen FE, et al,. (2002). The toll-like receptor TLR4 is necessary for lipopolysaccharide- induced oligodendrocyte injury in the CNS. J Neurosci 22: 2478-2486. (Pubitemid 37465796)
40. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
41. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 93: 239-245. (Pubitemid 32763181)
42. Manzaneres J, Corchero J, Romero JJ, Fernandez-Ruiz JA, Ramos JÁ FJA, (1999). Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20: 287-294. (Pubitemid 29301682)
43. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, et al,. (2010). The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 13: 951-957.
44. Mayer DJ, Mao J, Holt J, Price DD, (1999). Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci USA 96: 7731-7736. (Pubitemid 29328349)
45. 3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem 280: 19516-19526. (Pubitemid 41379472)
46. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, et al,. (2007). Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 72: 395-406. (Pubitemid 47124120)
47. 3 adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia 11: 1064-1073.
48. 2 receptors. Biochem Pharmacol 79: 471-477.
49. 2 receptor modulates microglial cells stimulated with lypopolysaccharide: role of ERK-1/2 kinase signalling in nitric oxide release. Br J Pharmacol 165: 1773-1788.
50. Molina-Holgado F, Lledo A, Guaza C, (1997). Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 8: 1929-1933. (Pubitemid 27314311)
51. 2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J Neurosci Res 67: 829-836. (Pubitemid 34226296)
52. Molina-Holgado F, Pinteaux E, Moore JD, Molina-Holgado E, Guaza C, Gibson RM, (2003). Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 23: 6470-6474. (Pubitemid 36909872)
53. Morel LJ, Giros B, Daugé V, (2009). Adolescent exposure to chronic delta-9-tetrahydrocannabinol blocks opiate dependence in maternally deprived rats. Neuropsychopharmacology 34: 2469-2476.
54. Olsen P, Rasmussen M, Zhu W, Tonnesen E, Stefano GB, (2005). Human gliomas contain morphine. Med Sci Monit 11: MS18-MS21. (Pubitemid 40790945)
55. Ortega-Gutiérrez S, Molina-Holgado E, Guaza C, (2005). Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 52: 163-168. (Pubitemid 41652920)
56. Parolaro D, Rubino T, Vigana D, Massi P, Guidali C, Realini N, (2010). Cellular mechanisms underlying the interaction between cannabinoid and opioid system. Curr Drug Targets 11: 393-405.
57. 2. Pharmacol Rev 62: 588-631.
58. Powell KJ, Hosokawa A, Bell A, Sutak M, Milne B, Quirion R, et al,. (1999). Comparative effects of cyclo-oxygenase and nitric oxide synthase inhibition on the development and reversal of spinal opioid tolerance. Br J Pharmacol 127: 631-644. (Pubitemid 29276648)
59. Puffenbarger RA, Boothe AC, Cabral GA, (2000). Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29: 58-69. (Pubitemid 30031134)
60. Raghavendra V, Rutkowski MD, DeLeo JA, (2002). The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci 22: 9980-9989. (Pubitemid 35332883)
61. Raghavendra V, Tanga FY, DeLeo JA, (2004). Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology 29: 327-334. (Pubitemid 38175151)
62. Richardson JD, (2000). Cannabinoids modulate pain by multiple mechanisms of action. J Pain 1: 2-14. (Pubitemid 30623460)
63. Romero-Sandoval EA, Horvath RJ, DeLeo JA, (2008). Neuroimmune interactions and pain: focus on glial-modulating targets. Curr Opin Investig Drugs 9: 726-734. (Pubitemid 351950869)
64. Romero-Sandoval EA, Horvath R, Landry RP, DeLeo JA, (2009). Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation. Mol Pain 5: 25.
65. Satoh M, Minami M, (1995). Molecular pharmacology of the opioid receptors. Pharmacol Ther 68: 343-364. (Pubitemid 26020722)
66. Scherle PA, Jones EA, Favata MF, Daulerio AJ, Covington MB, Nurnberg SA, et al,. (1998). Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes. J Immunol 161: 5681-5686. (Pubitemid 28519136)
67. Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, Peterson PK, (2005). Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49: 211-219. (Pubitemid 40188500)
68. Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T, (1997). Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 72: 169-177. (Pubitemid 27062773)
69. Song P, Zhao ZQ, (2001). The involvement of glial cells in the development of morphine tolerance. Neurosci Res 39: 281-286. (Pubitemid 32186379)
70. Stella N, (2010). Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58: 1017-1030.
71. Wang Z, Ma W, Chabot JG, Quirion R, (2009). Cell-type specific activation of p38 and ERK mediates calcitonin gene-related peptide involvement in tolerance to morphine-induced analgesia. FASEB J 23: 2576-2586.
72. Watkins LR, Milligan ED, Maier SF, (2001). Spinal cord glia: new players in pain. Pain 93: 201-205. (Pubitemid 32763176)
73. Watkins LR, Milligan ED, Maier SF, (2003). Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv Exp Med Biol 521: 1-21. (Pubitemid 36535161)
74. Watkins LR, Hutchinson MR, Johnston IN, Maier SF, (2005). Glia: novel counter-regulators of opioid analgesia. Trends Neurosci 28: 661-669. (Pubitemid 41654390)
75. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF, (2007). Norman Cousins Lecture. Glia as the 'bad guys': implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun 21: 131-146. (Pubitemid 46038918)
76. Watkins LR, Hutchinson MR, Rice KC, Maier SF, (2009). The 'toll' of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 30: 581-591.
77. Watters JJ, Sommer JA, Pfeiffer ZA, Prabhu U, Guerra AN, Bertics PJ, (2002). A differential role for the mitogen-activated protein kinases in lipopolysaccharide signaling: the MEK/ERK pathway is not essential for nitric oxide and interleukin 1beta production. J Biol Chem 277: 9077-9087. (Pubitemid 34952983)
78. Wilson AR, Maher L, Morgan MM, (2008). Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology 55: 1219-1225.
79. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J, (1998). Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 95: 15769-15774. (Pubitemid 29018775)
80. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J, (1999). A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96: 13496-13500.